Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Etentamig |
| Synonyms | |
| Therapy Description |
Etentamig (ABBV-383) is a bispecific antibody that targets alpha CD3 and BCMA, potentially resulting in the activation of T-cells and tumor cell lysis (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034, PMID: 36029527). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Etentamig | TNB-383B|TNB383B|TNB 383B|ABBV383|ABBV 383|ABBV-383 | CD3 Antibody 119 TNFRSF17 Antibody 22 | Etentamig (ABBV-383) is a bispecific antibody that targets alpha CD3 and BCMA, potentially resulting in the activation of T-cells and tumor cell lysis (Journal of Clinical Oncology 2018 36:15_suppl, 8034-8034, PMID: 36029527). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04453397 | Expanded access | Etentamig | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | No longer available | USA | 0 |
| NCT06158841 | Phase III | Dexamethasone + Elotuzumab + Pomalidomide Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Selinexor Etentamig | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | TUR | SWE | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | 7 |
| NCT05650632 | Phase I | Etentamig | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ISR | GBR | FRA | ESP | DNK | CAN | 0 |
| NCT06892522 | Phase Ib/II | Daratumumab + Dexamethasone + Lenalidomide Etentamig + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Etentamig Carfilzomib + Dexamethasone + Etentamig Etentamig Lenalidomide Daratumumab + Etentamig + Lenalidomide | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Recruiting | USA | ISR | AUS | 1 |
| NCT03933735 | Phase I | Etentamig | A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | DEU | 0 |
| NCT06223516 | Phase I | Etentamig | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ISR | DEU | 1 |
CKB BOOST